Condition: Pancreatic Cancer Stage III · Pancreatic Cancer Stage IV · Pancreatic Ductal Adenocarcinoma · Sponsor: Nuvance Health
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.
This description comes directly from the study's public registry record.
Pramila Krumholtz, RN · pramila.krumholtz@nuvancehealth.org
Tammy Lo, MSN · tammy.lo@nuvancehealth.org
Always discuss trial participation with your own doctor first.
| Nuvance Health | Norwalk, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04406831